Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis-Reference-Cited by-同舟云学术

Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis

Published:2014-07 Issue:1 Volume:86 Page:75-85
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Chow Bryna S. Man,Kocan Martina,Bosnyak Sanja,Sarwar Mohsin,Wigg Belinda,Jones Emma S.,Widdop Robert E.,Summers Roger J.,Bathgate Ross A.D.,Hewitson Tim D.,Samuel Chrishan S.

Publisher

Elsevier BV

Subject

Nephrology

Reference51 articles.

1. Progression in chronic kidney disease;Eddy;Adv Chronic Kidney Dis,2005

2. Cellular and molecular mechanisms of fibrosis;Wynn;J Pathol,2008

3. Molecular insights into renal interstitial fibrosis;Eddy;J Am Soc Nephrol,1996

4. Angiotensin II and renal fibrosis;Mezzano;Hypertension,2001

5. Transforming growth factor-β, basement membrane, and epithelial–mesenchymal transdifferentiation;Stahl;Am J Pathol,2001

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology;Biochemical Pharmacology;2024-09

2. Relaxin suppresses atrial fibrillation, reverses fibrosis and reduces inflammation in aged hearts;Biochemical Pharmacology;2024-09

3. Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study;Journal of the American Heart Association;2024-08-06

4. Cardiomyocyte-specific RXFP1 overexpression protects against pressure overload-induced cardiac dysfunction independently of relaxin;Biochemical Pharmacology;2024-07

5. The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin;Biochemical Pharmacology;2024-05